arrow
G

Gordon C. Jayson

University of Manchester
H指数:69
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK

西地尼布联合每周多西他赛或奥拉帕利与每周多西他赛对比治疗晚期或复发性子宫内膜癌(COPELIA):一项在英国进行的多中心、开放标签、随机、II期临床试验

2026-06-010
OAAI
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer

Ib期临床试验:评估SL-172154(一种双特异性CD47抑制剂和CD40激动剂Fc融合蛋白)联合mirvetuximab soravtansine或脂质体多柔比星治疗铂耐药性卵巢癌患者的疗效。

2026-04-080
PRE
The Incidence Of Breast Cancer In Ovarian Cancer Patients With BRCA Mutations: A Multicentre Retrospective Cohort Study.

BRCA突变卵巢癌患者中乳腺癌的发病率:一项多中心回顾性队列研究。

2025-02-010
PRE
The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors
2024-10-240
OAAI
ICON9: International phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy

ICON9: 国际III期随机研究,旨在评估奥拉帕利联合西地尼布或奥拉帕利单药维持治疗在铂类化疗有效后复发的铂敏感卵巢癌患者中的疗效。

2024-09-010
PRE
Association between chemotherapy response score (CRS) and tumour homologous recombination deficiency (tHRD) in women with newly diagnosed FIGO stage IIIC/IV high-grade serous ovarian cancer (HGSOC)

新诊断为FIGO分期IIIC/IV期的高级别浆液性卵巢癌(HGSOC)女性患者中,化疗反应评分(CRS)与肿瘤同源重组缺陷(tHRD)之间的关联。

2024-09-010
PRE
Testing unselected women with newly diagnosed high-grade serous ovarian cancer (HGSOC) for germline pathogenic variants (PVs) in mismatch repair (MMR) genes is unnecessary

对未经筛选的、新诊断为高级别浆液性卵巢癌(HGSOC)的女性进行错配修复(MMR)基因的胚系致病变异(PVs)检测是不必要的。

2024-09-010
PRE